Table 2

Proportion (%) of progressors by age and SE at baseline and gender

TotalPrescription between 12 and 26 monthsProgressors
NN%N%p
Age 14–29167 20487 63152.410 19011.6
Age<0.0001
14–1523 46316 12468.7293418.2
16–1721 09313 88065.8193613.9
18–1920 04411 29956.4146813.0
20–2119 994999650.0102010.2
22–2319 867932546.98989.6
24–2520 522909444.37268.0
26–2720 953905243.26437.1
28–2921 268886141.75656.4
SE<0.0001
]−1 ; −0.5]32 38717 05952.7170410.0
]−2 ; −1]47 00824 33951.8272011.2
]−3 ; −2]30 87216 03551.9179411.2
]−4 ; −3]20 75811 01553.1131311.9
]−5; −4]13 853732752.994312.9
]−6; −5]8862480854.363713.2
≤−613 464704852.3107915.3
Gender<0.0001
F102 79455 17853.7646111.7
M64 41032 45350.4372911.5
Age 30–100463 283178 88638.610 5495.9
Age<0.0001
30–3454 56221 64639.710454.8
35–3953 16420 57438.78134.0
40–4462 39725 22240.410584.2
45–4967 31328 12741.811474.1
50–5456 18420 67136.87653.7
55–5944 61715 44934.66864.4
60–6435 98812 06933.58597.1
65–6929 93710 89536.4121411.1
70–7419 810786339.799812.7
75–7917 240692640.287612.6
80–8413 665561641.159610.6
85–1008406382845.549212.9
SE<0.0001
]−1; −0.5]91 61236 30339.619845.5
]−2; −1]129 63149 52638.228375.7
]−3; −2]80 54730 74438.216525.4
]−4; −3]54 99821 23738.611725.5
]−5; −4]36 56313 72937.57785.7
]−6; −5]25 029972738.95856.0
≤−644 90317 62039.215418.7
Gender<0.0001
F274 053110 34540.362605.7
M189 23068 54136.242896.3
  • Progressors are individuals with a progression rate of more than −0.50 diopters per year in the first 12–26 months after baseline. Multivariate logistic regression type III p-values are displayed.

  • SE, spherical equivalent.